StockData
NeuroPace Inc logo

NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/3028% above fair value
$8.20+0.23 (+2.89%)

Close on Nov 17, 2026Market cap $281.46MP/E –Yield 0.00%

NeuroPace revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

NeuroPace's revenue for the twelve months ending Jun 30, 2026 was $98.84M, up 16.9% year over year. For fiscal 2025 it was $99.99M, up 25.1% from the year before. The highest annual figure on record is $99.99M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$99.99M+25.1%
FY2024Dec 31, 2024$79.91M+22.1%
FY2023Dec 31, 2023$65.42M+43.7%
FY2022Dec 31, 2022$45.52M+0.7%
FY2021Dec 31, 2021$45.18M+9.8%
FY2020Dec 31, 2020$41.14M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.83M+17.1%
Q1 FY2026Mar 31, 2026$22.07M-2.0%
Q4 FY2025Dec 31, 2025$26.59M+23.9%
Q3 FY2025Sep 30, 2025$27.35M+29.9%
Q2 FY2025Jun 30, 2025$19.50M+1.3%
Q1 FY2025Mar 31, 2025$22.52M+24.3%
Q4 FY2024Dec 31, 2024$21.47M+19.2%
Q3 FY2024Sep 30, 2024$21.06M+28.2%
Q2 FY2024Jun 30, 2024$19.26M+16.6%
Q1 FY2024Mar 31, 2024$18.12M+25.2%
Q4 FY2023Dec 31, 2023$18.01M+40.8%
Q3 FY2023Sep 30, 2023$16.43M+47.2%
Q2 FY2023Jun 30, 2023$16.51M+61.9%
Q1 FY2023Mar 31, 2023$14.47M+27.2%
Q4 FY2022Dec 31, 2022$12.79M+16.3%
Q3 FY2022Sep 30, 2022$11.16M+7.9%
Q2 FY2022Jun 30, 2022$10.20M-19.2%
Q1 FY2022Mar 31, 2022$11.37M+1.4%
Q4 FY2021Dec 31, 2021$11.00M+2.3%
Q3 FY2021Sep 30, 2021$10.34M-19.0%
Q2 FY2021Jun 30, 2021$12.63M+65.3%
Q1 FY2021Mar 31, 2021$11.22M+12.5%
Q4 FY2020Dec 31, 2020$10.75M–
Q3 FY2020Sep 30, 2020$12.77M–
Q2 FY2020Jun 30, 2020$7.64M–
Q1 FY2020Mar 31, 2020$9.98M–

More NeuroPace figures

See a number that looks wrong?